Efforts have been made to combine radiographic biomarkers such as bronchiectasis or bronchial wall thickness (BWT) for the purpose of identifying asthma subphenotypes and their clinical implications.
Objective
Our aim was to assess whether a composite triple radiologic phenotype measured by high-resolution computed tomography comprising BWT, mucus plug score (MPS), and mediastinal lymph node (MLN) size might provide a better insight into subphenotypes in persistent asthma.
Methods
A total of 112 patients with moderate-to-severe asthma were included in this retrospective observational study. A binary method was used to classify patients according to median values for the following: a pooled mediastinal lymph node size of 3.6 mm or more; a BWT as a pooled wall area of at least 50% of the total airway area; and a mucus plug score of 1 or higher, with a mucus plug considered positive if complete bronchial obstruction was imaged more than 2 cm from a pleural surface.
Results
Patients with the triple imaging phenotype exhibited significantly worse Asthma Control Questionnaire scores, with their scores exceeding minimal clinical important difference, a higher prevalence of concomitant chronic rhinosinusitis with nasal polyps, and a greater total IgE level.
Conclusion
We have demonstrated an association between poorer symptom control and the triple radiologic asthma phenotype.
{"title":"The triple radiologic asthma phenotype is associated with worse disease control","authors":"Rory Chan MBChB, PhD , Chary Duraikannu FRCR , Mohamed Jaushal Thouseef FRCR , Brian Lipworth MD","doi":"10.1016/j.jacig.2024.100341","DOIUrl":"10.1016/j.jacig.2024.100341","url":null,"abstract":"<div><h3>Background</h3><div>Efforts have been made to combine radiographic biomarkers such as bronchiectasis or bronchial wall thickness (BWT) for the purpose of identifying asthma subphenotypes and their clinical implications.</div></div><div><h3>Objective</h3><div>Our aim was to assess whether a composite triple radiologic phenotype measured by high-resolution computed tomography comprising BWT, mucus plug score (MPS), and mediastinal lymph node (MLN) size might provide a better insight into subphenotypes in persistent asthma.</div></div><div><h3>Methods</h3><div>A total of 112 patients with moderate-to-severe asthma were included in this retrospective observational study. A binary method was used to classify patients according to median values for the following: a pooled mediastinal lymph node size of 3.6 mm or more; a BWT as a pooled wall area of at least 50% of the total airway area; and a mucus plug score of 1 or higher, with a mucus plug considered positive if complete bronchial obstruction was imaged more than 2 cm from a pleural surface.</div></div><div><h3>Results</h3><div>Patients with the triple imaging phenotype exhibited significantly worse Asthma Control Questionnaire scores, with their scores exceeding minimal clinical important difference, a higher prevalence of concomitant chronic rhinosinusitis with nasal polyps, and a greater total IgE level.</div></div><div><h3>Conclusion</h3><div>We have demonstrated an association between poorer symptom control and the triple radiologic asthma phenotype.</div></div>","PeriodicalId":75041,"journal":{"name":"The journal of allergy and clinical immunology. Global","volume":"3 4","pages":"Article 100341"},"PeriodicalIF":0.0,"publicationDate":"2024-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142427957","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
We present a case of secondary T-cell deficiency particularly affecting CD4 T cells, along with the emergence of chronic spontaneous urticaria in a patient following COVID-19 vaccination. The condition was partially managed with omalizumab after initial first-line therapy proved ineffective.
我们报告了一例继发性 T 细胞缺乏症病例，患者在接种 COVID-19 疫苗后出现慢性自发性荨麻疹，尤其是 CD4 T 细胞。在最初的一线治疗无效后，患者使用奥马珠单抗部分控制了病情。
{"title":"Case report of secondary T-cell deficiency following the AstraZeneca COVID-19 vaccine","authors":"Amin Esmailian BSC (Hons), MD , Sara Laura Barnes MBBS (Hons), MBA, FRACP, ADJAOP , Marsus Pumar BBiomedSc (Hons), BMBS, MPhil","doi":"10.1016/j.jacig.2024.100339","DOIUrl":"10.1016/j.jacig.2024.100339","url":null,"abstract":"<div><div>We present a case of secondary T-cell deficiency particularly affecting CD4 T cells, along with the emergence of chronic spontaneous urticaria in a patient following COVID-19 vaccination. The condition was partially managed with omalizumab after initial first-line therapy proved ineffective.</div></div>","PeriodicalId":75041,"journal":{"name":"The journal of allergy and clinical immunology. Global","volume":"3 4","pages":"Article 100339"},"PeriodicalIF":0.0,"publicationDate":"2024-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772829324001358/pdfft?md5=18984cb165c25986a8596a564a6b8786&pid=1-s2.0-S2772829324001358-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142314326","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-09-01DOI: 10.1016/j.jacig.2024.100338
Alexander Egeberg MD, PhD , Andreas Wollenberg MD , Thomas Bieber MD, PhD , Adina R. Lemeshow PhD , Shefali Vyas MD
Background
The risk of cardiovascular disease in atopic dermatitis (AD) is not well established.
Objectives
Our aims were to evaluate the incidence rate (IR) of venous thromboembolism (VTE) in patients with AD in a population-based cohort study and to assess atherosclerotic cardiovascular disease (ASCVD) risk factors and incidence of malignancies, major adverse cardiovascular events (MACE), and VTE in patients with AD and rheumatoid arthritis (RA) in a nested cohort analysis.
Methods
Data from individuals age 12 years or older (nested cohort age ≥ 18 years) from January 1, 2000, to December 31, 2018, were extracted from the Danish National Patient Registry. Patients with AD were age- and sex-matched with 10 healthy controls. ASCVD risk factors included age 65 years or older and history of smoking, coronary artery disease, stroke, deep vein thrombosis (DVT), pulmonary embolism (PE), and malignancy.
Results
The population-based cohort comprised 190,751 patients (17,341 patients with AD and 173,410 healthy controls). The IRs per 100 patient-years were comparable between the AD cohort and healthy controls for VTE (0.14 [95% CI = 0.12-0.16] vs 0.11 [95% CI = 0.11-0.12]), DVT (0.08 [95% CI = 0.06-0.09] vs 0.06 [95% CI = 0.06-0.07]), and PE (0.06 [95% CI = 0.05-0.08] vs 0.05 [95% CI = 0.05-0.05]). The IR for VTE was higher in the AD cohort age 65 years or older (0.71 [95% CI = 0.56-0.90]) than in the age-matched controls (0.50 [95% CI = 0.46-0.54]). ASCVD risk factors were more frequent in the patients with RA than in the patients with AD. The IRs for malignancies and MACE were higher with specific ASCVD risk factors.
Conclusions
The IRs of cardiovascular events were comparable between the AD cohort and general population. The risk of VTE, malignancy, or MACE was higher with specific ASCVD risk factors, underscoring the need for patient monitoring.
背景特应性皮炎（AD）患者的心血管疾病风险尚未得到很好的确定。目的我们的目的是在一项基于人群的队列研究中评估AD患者静脉血栓栓塞症（VTE）的发病率（IR），并在一项嵌套队列分析中评估AD和类风湿性关节炎（RA）患者的动脉粥样硬化性心血管疾病（ASCVD）风险因素以及恶性肿瘤、主要不良心血管事件（MACE）和VTE的发病率。方法从丹麦国家患者登记处提取了2000年1月1日至2018年12月31日期间12岁或12岁以上（嵌套队列年龄≥18岁）患者的数据。AD患者与10名健康对照者进行了年龄和性别匹配。ASCVD风险因素包括65岁或以上、吸烟史、冠心病、中风、深静脉血栓形成（DVT）、肺栓塞（PE）和恶性肿瘤。AD队列和健康对照组每100患者年的VTE（0.14 [95% CI = 0.12-0.16] vs 0.11 [95% CI = 0.11-0.12]）、DVT（0.08 [95% CI = 0.06-0.09] vs 0.06 [95% CI = 0.06-0.07]）和PE（0.06 [95% CI = 0.05-0.08] vs 0.05 [95% CI = 0.05-0.05]）IR值相当。与年龄匹配的对照组（0.50 [95% CI = 0.46-0.54]）相比，65 岁或以上的 AD 组群的 VTE IR（0.71 [95% CI = 0.56-0.90]）更高。ASCVD风险因素在RA患者中的出现频率高于AD患者。结论AD队列和普通人群的心血管事件发生率相当。发生 VTE、恶性肿瘤或 MACE 的风险与特定的 ASCVD 风险因素有关，因此需要对患者进行监测。
{"title":"Incidence of cardiovascular events in a population-based Danish cohort with atopic dermatitis","authors":"Alexander Egeberg MD, PhD , Andreas Wollenberg MD , Thomas Bieber MD, PhD , Adina R. Lemeshow PhD , Shefali Vyas MD","doi":"10.1016/j.jacig.2024.100338","DOIUrl":"10.1016/j.jacig.2024.100338","url":null,"abstract":"<div><h3>Background</h3><div>The risk of cardiovascular disease in atopic dermatitis (AD) is not well established.</div></div><div><h3>Objectives</h3><div>Our aims were to evaluate the incidence rate (IR) of venous thromboembolism (VTE) in patients with AD in a population-based cohort study and to assess atherosclerotic cardiovascular disease (ASCVD) risk factors and incidence of malignancies, major adverse cardiovascular events (MACE), and VTE in patients with AD and rheumatoid arthritis (RA) in a nested cohort analysis.</div></div><div><h3>Methods</h3><div>Data from individuals age 12 years or older (nested cohort age ≥ 18 years) from January 1, 2000, to December 31, 2018, were extracted from the Danish National Patient Registry. Patients with AD were age- and sex-matched with 10 healthy controls. ASCVD risk factors included age 65 years or older and history of smoking, coronary artery disease, stroke, deep vein thrombosis (DVT), pulmonary embolism (PE), and malignancy.</div></div><div><h3>Results</h3><div>The population-based cohort comprised 190,751 patients (17,341 patients with AD and 173,410 healthy controls). The IRs per 100 patient-years were comparable between the AD cohort and healthy controls for VTE (0.14 [95% CI = 0.12-0.16] vs 0.11 [95% CI = 0.11-0.12]), DVT (0.08 [95% CI = 0.06-0.09] vs 0.06 [95% CI = 0.06-0.07]), and PE (0.06 [95% CI = 0.05-0.08] vs 0.05 [95% CI = 0.05-0.05]). The IR for VTE was higher in the AD cohort age 65 years or older (0.71 [95% CI = 0.56-0.90]) than in the age-matched controls (0.50 [95% CI = 0.46-0.54]). ASCVD risk factors were more frequent in the patients with RA than in the patients with AD. The IRs for malignancies and MACE were higher with specific ASCVD risk factors.</div></div><div><h3>Conclusions</h3><div>The IRs of cardiovascular events were comparable between the AD cohort and general population. The risk of VTE, malignancy, or MACE was higher with specific ASCVD risk factors, underscoring the need for patient monitoring.</div></div>","PeriodicalId":75041,"journal":{"name":"The journal of allergy and clinical immunology. Global","volume":"3 4","pages":"Article 100338"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142326999","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-09-01DOI: 10.1016/j.jacig.2024.100337
Aiwei Yan MD , Edward Fernandez MD , Matthew Steven Krantz MD , Basil M. Kahwash MD , Elizabeth J. Phillips MD , Cosby A. Stone Jr. MD, MPH
We aim to bring awareness of allergies to excipients such as carboxymethylcellulose as “hidden dangers” that can be easily missed in diagnosis, leading to severe effects on patient health, and falsely limit the drug treatments that a patient can receive.
{"title":"Carboxymethylcellulose: A hidden culprit in immediate hypersensitivity reactions after triamcinolone injections","authors":"Aiwei Yan MD , Edward Fernandez MD , Matthew Steven Krantz MD , Basil M. Kahwash MD , Elizabeth J. Phillips MD , Cosby A. Stone Jr. MD, MPH","doi":"10.1016/j.jacig.2024.100337","DOIUrl":"10.1016/j.jacig.2024.100337","url":null,"abstract":"<div><div>We aim to bring awareness of allergies to excipients such as carboxymethylcellulose as “hidden dangers” that can be easily missed in diagnosis, leading to severe effects on patient health, and falsely limit the drug treatments that a patient can receive.</div></div>","PeriodicalId":75041,"journal":{"name":"The journal of allergy and clinical immunology. Global","volume":"3 4","pages":"Article 100337"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772829324001334/pdfft?md5=23fef908c2b03bf14f54458265c5a4f2&pid=1-s2.0-S2772829324001334-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142315435","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-08-30DOI: 10.1016/j.jacig.2024.100331
Hineptch Daungsupawong PhD , Viroj Wiwanitkitb MD
{"title":"COVID-19 vaccine uptake among young adults and influence of asthma","authors":"Hineptch Daungsupawong PhD , Viroj Wiwanitkitb MD","doi":"10.1016/j.jacig.2024.100331","DOIUrl":"10.1016/j.jacig.2024.100331","url":null,"abstract":"","PeriodicalId":75041,"journal":{"name":"The journal of allergy and clinical immunology. Global","volume":"3 4","pages":"Article 100331"},"PeriodicalIF":0.0,"publicationDate":"2024-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772829324001279/pdfft?md5=2b100bbed9cd6477c993c1a627bd3d9e&pid=1-s2.0-S2772829324001279-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142162366","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-08-28DOI: 10.1016/j.jacig.2024.100330
Simon Høj BSc , Simon Francis Thomsen MD, PhD, DMSci , Charlotte Suppli Ulrik MD, PhD, DMSci , Hanieh Meteran MD , Torben Sigsgaard MD, PhD , Howraman Meteran MD, PhD
Background
This study assessed the reliability of ChatGPT as a source of information on asthma, given the increasing use of artificial intelligence–driven models for medical information. Prior concerns about misinformation on atopic diseases in various digital platforms underline the importance of this evaluation.
Objective
We aimed to evaluate the scientific reliability of ChatGPT as a source of information on asthma.
Methods
The study involved analyzing ChatGPT’s responses to 26 asthma-related questions, each followed by a follow-up question. These encompassed definition/risk factors, diagnosis, treatment, lifestyle factors, and specific clinical inquiries. Medical professionals specialized in allergic and respiratory diseases independently assessed the responses using a 1-to-5 accuracy scale.
Results
Approximately 81% of the responses scored 4 or higher, suggesting a generally high accuracy level. However, 5 responses scored >3, indicating minor potentially harmful inaccuracies. The overall median score was 4. Fleiss multirater kappa value showed moderate agreement among raters.
Conclusion
ChatGPT generally provides reliable asthma-related information, but its limitations, such as lack of depth in certain responses and inability to cite sources or update in real time, were noted. It shows promise as an educational tool, but it should not be a substitute for professional medical advice. Future studies should explore its applicability for different user demographics and compare it with newer artificial intelligence models.
{"title":"Evaluating the scientific reliability of ChatGPT as a source of information on asthma","authors":"Simon Høj BSc , Simon Francis Thomsen MD, PhD, DMSci , Charlotte Suppli Ulrik MD, PhD, DMSci , Hanieh Meteran MD , Torben Sigsgaard MD, PhD , Howraman Meteran MD, PhD","doi":"10.1016/j.jacig.2024.100330","DOIUrl":"10.1016/j.jacig.2024.100330","url":null,"abstract":"<div><h3>Background</h3><p>This study assessed the reliability of ChatGPT as a source of information on asthma, given the increasing use of artificial intelligence–driven models for medical information. Prior concerns about misinformation on atopic diseases in various digital platforms underline the importance of this evaluation.</p></div><div><h3>Objective</h3><p>We aimed to evaluate the scientific reliability of ChatGPT as a source of information on asthma.</p></div><div><h3>Methods</h3><p>The study involved analyzing ChatGPT’s responses to 26 asthma-related questions, each followed by a follow-up question. These encompassed definition/risk factors, diagnosis, treatment, lifestyle factors, and specific clinical inquiries. Medical professionals specialized in allergic and respiratory diseases independently assessed the responses using a 1-to-5 accuracy scale.</p></div><div><h3>Results</h3><p>Approximately 81% of the responses scored 4 or higher, suggesting a generally high accuracy level. However, 5 responses scored >3, indicating minor potentially harmful inaccuracies. The overall median score was 4. Fleiss multirater kappa value showed moderate agreement among raters.</p></div><div><h3>Conclusion</h3><p>ChatGPT generally provides reliable asthma-related information, but its limitations, such as lack of depth in certain responses and inability to cite sources or update in real time, were noted. It shows promise as an educational tool, but it should not be a substitute for professional medical advice. Future studies should explore its applicability for different user demographics and compare it with newer artificial intelligence models.</p></div>","PeriodicalId":75041,"journal":{"name":"The journal of allergy and clinical immunology. Global","volume":"3 4","pages":"Article 100330"},"PeriodicalIF":0.0,"publicationDate":"2024-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772829324001267/pdfft?md5=31dff3c3eab39fc9f40519b2c8ca51eb&pid=1-s2.0-S2772829324001267-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142240525","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Acidic oral environments may trigger systemic contact dermatitis via ionization of metals, including palladium. A patch test revealed a late delayed positive response to palladium, emphasizing the need for nuanced diagnostic approaches for allergy management.
Pub Date : 2024-08-28DOI: 10.1016/j.jacig.2024.100335
Marco Dubini MD , Patrizia Pignatti PhD , Federica Rivolta MD , Antonella Gurrado BSc , Paolo Marraccini MD
The use of erythritol as a food sweetener has spread significantly from Japan throughout the world. We describe a case of severe anaphylaxis due to immediate-type allergy to erythritol that was diagnosed with in vitro basophil activation tests and in vivo skin tests.
{"title":"The first case of erythritol-induced anaphylaxis in Europe diagnosed with skin tests and basophil activation tests","authors":"Marco Dubini MD , Patrizia Pignatti PhD , Federica Rivolta MD , Antonella Gurrado BSc , Paolo Marraccini MD","doi":"10.1016/j.jacig.2024.100335","DOIUrl":"10.1016/j.jacig.2024.100335","url":null,"abstract":"<div><p>The use of erythritol as a food sweetener has spread significantly from Japan throughout the world. We describe a case of severe anaphylaxis due to immediate-type allergy to erythritol that was diagnosed with <em>in vitro</em> basophil activation tests and <em>in vivo</em> skin tests.</p></div>","PeriodicalId":75041,"journal":{"name":"The journal of allergy and clinical immunology. Global","volume":"3 4","pages":"Article 100335"},"PeriodicalIF":0.0,"publicationDate":"2024-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772829324001310/pdfft?md5=ed7e3be22d234629a978b27fed6d9c70&pid=1-s2.0-S2772829324001310-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142238847","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
A patient with GATA2 deficiency developed corticosteroid-responsive sterile granulomatous lung disease despite monocytopenia. The presence of B-lymphopenia, autoimmunity, an elevated level of serum B-cell–activating factor, and pulmonary plasma cell infiltration, which together suggested an underlying mechanism similar to that of combined variable immunodeficiency lung disease.
一名 GATA2 缺乏症患者尽管出现了单核细胞减少，但却患上了皮质类固醇反应性无菌肉芽肿肺病。患者出现 B 淋巴细胞减少、自身免疫、血清 B 细胞激活因子水平升高和肺浆细胞浸润，这些因素共同提示其潜在机制类似于合并变异性免疫缺陷肺病。
{"title":"BAFF-associated granulomatous lung disease in a patient with GATA2 deficiency","authors":"Motoko Yasutomi-Sakai MD, PhD , Taihei Hayashi MD, PhD , Koji Suzuki MD, PhD , Hayaki Akeda MD , Yumekichi Maeda MD, PhD , Akitoshi Okada MD , Toshihiro Takeda MD , Yasuhiro Watanabe MD , Yoshiaki Imamura MD, PhD , Yusei Ohshima MD, PhD","doi":"10.1016/j.jacig.2024.100336","DOIUrl":"10.1016/j.jacig.2024.100336","url":null,"abstract":"<div><p>A patient with GATA2 deficiency developed corticosteroid-responsive sterile granulomatous lung disease despite monocytopenia. The presence of B-lymphopenia, autoimmunity, an elevated level of serum B-cell–activating factor, and pulmonary plasma cell infiltration, which together suggested an underlying mechanism similar to that of combined variable immunodeficiency lung disease.</p></div>","PeriodicalId":75041,"journal":{"name":"The journal of allergy and clinical immunology. Global","volume":"3 4","pages":"Article 100336"},"PeriodicalIF":0.0,"publicationDate":"2024-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772829324001322/pdfft?md5=9faac18996a29cf60cb46ce01563dc80&pid=1-s2.0-S2772829324001322-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142240527","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-08-28DOI: 10.1016/j.jacig.2024.100334
Simona Boccaletti MSc , Rafael Alfonso-Cristancho PhD , Waseem Ahmed MBA , Lehanne Sergison , Adaeze Eze MSc , Prashant Auti MS (Pharm) , Cathelijne Alleman MSc , Lohit Badgujar PhD , Nicholas Halfpenny MSc , Dorothea Heldt MSc
Background
Several biologics for the treatment of severe asthma are available as self-administration devices.
Objective
We performed a systematic literature review to understand the use, benefits, and challenges of these self-administration devices.
Methods
Electronic databases and conference proceedings were searched using terms for asthma, biologic treatment, and at-home/self-administration (GSK study 213094). Publications were scanned for relevance using prespecified Population, Intervention, Comparison, Outcomes, Study Design (PICOS) criteria. Data on efficacy, safety, patient experience, and economic outcomes were extracted; study quality was assessed. A firsthand patient perspective was obtained.
Results
Thirty-five of 504 records met the inclusion criteria. Across four phase 3 studies, ≥95% of biologic self-administrations were successful on the basis of predefined criteria. At-home self-administration was preferred over in-clinic administration by 43-96% of patients across 5 studies. Most patients (≥89%) in two phase 3 studies reported completing self-administration easily without repeated reference to instructions; high proportions of patients (≥98%) were confident in their ability to self-administer their biologic, and ≥96% rated it as extremely, very or moderately easy to self-administer. Across 16 studies reporting efficacy data, there was evidence of reduced blood eosinophil counts and improved asthma control with biologic self-administration, with improved health-related quality of life shown across 6 studies. Economic outcomes data were limited. From a patient perspective, autonomy is the major benefit of self-administration.
Conclusion
Although more evidence is needed, this systematic literature review provides consistent evidence of high injection success rates and, supported by a patient perspective, preference for self-administration of biologics among patients with severe asthma.
{"title":"Systematic literature review of asthma biologic self-administration enhanced by a patient perspective","authors":"Simona Boccaletti MSc , Rafael Alfonso-Cristancho PhD , Waseem Ahmed MBA , Lehanne Sergison , Adaeze Eze MSc , Prashant Auti MS (Pharm) , Cathelijne Alleman MSc , Lohit Badgujar PhD , Nicholas Halfpenny MSc , Dorothea Heldt MSc","doi":"10.1016/j.jacig.2024.100334","DOIUrl":"10.1016/j.jacig.2024.100334","url":null,"abstract":"<div><h3>Background</h3><div>Several biologics for the treatment of severe asthma are available as self-administration devices.</div></div><div><h3>Objective</h3><div>We performed a systematic literature review to understand the use, benefits, and challenges of these self-administration devices.</div></div><div><h3>Methods</h3><div>Electronic databases and conference proceedings were searched using terms for asthma, biologic treatment, and at-home/self-administration (GSK study 213094). Publications were scanned for relevance using prespecified Population, Intervention, Comparison, Outcomes, Study Design (PICOS) criteria. Data on efficacy, safety, patient experience, and economic outcomes were extracted; study quality was assessed. A firsthand patient perspective was obtained.</div></div><div><h3>Results</h3><div>Thirty-five of 504 records met the inclusion criteria. Across four phase 3 studies, ≥95% of biologic self-administrations were successful on the basis of predefined criteria. At-home self-administration was preferred over in-clinic administration by 43-96% of patients across 5 studies. Most patients (≥89%) in two phase 3 studies reported completing self-administration easily without repeated reference to instructions; high proportions of patients (≥98%) were confident in their ability to self-administer their biologic, and ≥96% rated it as extremely, very or moderately easy to self-administer. Across 16 studies reporting efficacy data, there was evidence of reduced blood eosinophil counts and improved asthma control with biologic self-administration, with improved health-related quality of life shown across 6 studies. Economic outcomes data were limited. From a patient perspective, autonomy is the major benefit of self-administration.</div></div><div><h3>Conclusion</h3><div>Although more evidence is needed, this systematic literature review provides consistent evidence of high injection success rates and, supported by a patient perspective, preference for self-administration of biologics among patients with severe asthma.</div></div>","PeriodicalId":75041,"journal":{"name":"The journal of allergy and clinical immunology. Global","volume":"3 4","pages":"Article 100334"},"PeriodicalIF":0.0,"publicationDate":"2024-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772829324001309/pdfft?md5=d952829a934e948b9e28bfd850c74b84&pid=1-s2.0-S2772829324001309-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142315433","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号